Company

Bioventix (LSE:BVXP)

Bioventix develops high-affinity sheep monoclonal antibodies for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.

About BVXP

Related Articles

Investing Articles

2 secret growth stocks I think are worth adding to your watchlist

Paul Summers highlights two under-the-radar stocks he thinks warrant more attention from growth investors.

Read more »

Investing Articles

2 secret small-cap growth stocks I think you need to know about

These market minnows have been quietly making their owners a lot of money. Paul Summers take a closer look.

Read more »

Dial being turned up to 'high'
Investing Articles

Why I think this top small-cap stock could make you a fortune

If you’re looking for a company that could produce triple-digit returns then I’d check out this little known small-cap.

Read more »

Investing Articles

A FTSE 100 dividend growth stock I’d buy today and one top performer I’d consider selling

Why I’d recycle my profits from this small-cap into this evergreen FTSE 100 (INDEXFTSE: UKX) big-cap.

Read more »

Investing Articles

Why I’d buy AstraZeneca plc over this soaring growth stock

Harvey Jones says AstraZeneca plc (LON: AZN) could hit new peaks and put this biotechnology upstart in its place.

Read more »

Investing Articles

Should you buy this growth company after profits soar 40%?

The market reacted negatively to this company's explosive profit growth today. One Fool takes a closer look.

Read more »

Investing Articles

Why this small-cap stock could be the UK’s most exciting investment opportunity right now

Edward Sheldon identifies a fast-growing small-cap biotech stock that he believes has considerable potential.

Read more »

Investing Articles

These small-cap growth stocks could be millionaire-makers

I think these two growers look set to advance further.

Read more »

Investing Articles

2 small-cap stocks I’d buy right now

One Fool has found two compelling small-cap growth opportunities for your consideration.

Read more »

Investing Articles

Should you buy this stock after it reports a 27% rise in revenue?

Is this company set to soar after positive results?

Read more »